The Largest Online Global Physicians Community



Connect Globally Expand your medical network and Connect with physicians worldwide. Consult & Share with colleagues at your specialty. Choose the specialty channels of your interest.
Discuss Discuss & Collaborate with colleagues at your specialty and other specialties. Share your insights, experience and opinions. Comment to posts and publications of peers. Post text, pictures, videos and files using your real name or stay anonymous.
Stay Updated Case Studies, Medical Publications updates by specialty, E- Learning courses and second opinionfrom colleagues. Library by Specialty: Share & download files, presentation and images by specialty and topics. PubMed publications alerts
Groups Join and Create physician group & experts panels. Common interest, idea, activity or event. Online "Round Table" of specialist. Medical topic groups, Researches groups, Department groups, Management groups, Event groups, Ad hoc groups.
Research Manage & Communicate with all research sites through one international secure network. Promote your research & request for patient recruitment.
Honoraria Earn Honoraria for your knowledge and expertise. Participate in Surveys, Focus groups and Experts Panels, 2nd opinion consultations, Job offers.
Sign Up to Join G-Med

Already a member? Log in.
Featured Posts

US Case Reports of Cerebral Venous Sinus Thrombosis With Thrombocytopenia After Ad26.COV2.S Vaccination, March 2 to April 21, 2021

A case series published in JAMA describes the clinical characteristics of the first US patients reported to have cerebral venous sinus thrombosis (CVST) with thrombocytopenia following receipt of the Ad26.COV2.S (Janssen/Johnson & Johnson) coronavirus disease 2019 (COVID-19) vaccine. 

The case series included 12 patients with CVST and thrombocytopenia after receipt of the Ad26.COV2.S vaccine, administered as a single dose, reported to the Vaccine Adverse Event Reporting System as of April 21, 2021. Of the patients, 8 were in the age range of 18-39 years, while the remaining 4 were ≥40 years; all were women. The median interval from vaccination to symptom onset was 8 days (range, 6-15 days). 

NYC, NJ, and Connecticut to Ease COVID-19 Capacity Restrictions

TUESDAY, May 4, 2021 (HealthDay News) -- Shops, restaurants, theaters, and other businesses in New York, New Jersey, and Connecticut will be allowed to operate at full capacity starting May 19 as long as there is space for people to maintain 6 feet of social distance, the three states announced Monday.

Also on Monday, Florida ended all COVID-19 restrictions. Gov. Ron DeSantis suspended all local COVID-19 emergency mandates immediately and issued an executive order to outlaw all local COVID-19 emergency mandates in the state, effective July 1. He noted that the supply of COVID-19 vaccines in the state has now exceeded demand.

But while many parts of the United States are opening back up, nearly half of Oregon was shut back down by Gov. Kate Brown due to one of the largest increases in infections nationwide, CBS News reported. Brown declared 15 counties an "extreme risk" and banned all indoor dining and limited gyms and indoor entertainment spaces to six people at one time.

"This virus is like a sucker punch. You never know when it's going to get you," Brown said, CBS News reported. "Right now, it's truly a race between the variants and the vaccines. Obviously the variants are winning. But over the next couple of weeks, I'm confident we can beat it back."

CBS News Article

Copyright © 2020 HealthDay. All rights reserved.

Side Effects of BNT162b2, ChAdOx1 nCoV-19 Vaccines Quantified

Systemic and local side effects to BNT162b2 and ChAdOx1 nCoV-19 vaccines occur at relatively low frequencies, according to a study published online April 27 in The Lancet Infectious Diseases.

Cristina Menni, Ph.D., from King's College London, and colleagues conducted a prospective observational study to examine the proportion and probability of self-reported systemic and local side effects within eight days of vaccination among individuals receiving one or two doses of the BNT162b2 vaccine or one dose of the ChAdOx1 nCoV-19 vaccine.

A total of 627,383 individuals reported being vaccinated with 655,590 doses between Dec. 8, 2020, and March 10, 2021. The researchers found that systemic side effects were reported by 13.5 and 22.0 percent of individuals after the first and second doses of BNT162b2, respectively, and by 33.7 percent after their first dose of ChAdOx1 nCoV-19. Local side effects were reported by 71.9 and 68.5 percent after the first and second doses of BNT162b2, respectively, and by 58.7 percent after the first dose of ChAdOx1 nCoV-19. Compared with those without known past infection, systemic side effects were more common after the first BNT162b2 and ChAdOx1 nCoV-19 doses (1.6 and 2.9 times, respectively) among individuals with previous severe acute respiratory syndrome coronavirus 2 infection. Starting 12 days after the first dose, there was a significant reduction in the infection risk, reaching 60 percent for ChAdOx1 nCoV-19 and 69 and 72 percent for BNT162b2 at 21 to 44 and 45 to 59 days, respectively.

"Short-term adverse effects of both vaccines are moderate in frequency, mild in severity, and short-lived," the authors write.

Several authors disclosed financial ties to pharmaceutical companies, including Pfizer and AstraZeneca, and to ZOE Global.

Abstract/Full Text


Copyright © 2020 HealthDay. All rights reserved. 

ART Ups Life Expectancy for HIV+ in Latin America, Caribbean

FRIDAY, April 30, 2021 (HealthDay News) -- Life expectancy among people with HIV receiving antiretroviral therapy (ART) has significantly improved in Latin America and the Caribbean, according to a study published in the May 1 issue of The Lancet HIV.

Casey L. Smiley, M.D., from the Vanderbilt University Medical Center in Nashville, Tennessee, and colleagues assessed life expectancy trends from 2003 to 2017 among people aged 16 years and older with HIV beginning treatment with ART in Argentina, Brazil, Chile, Haiti, Honduras, Mexico, and Peru. The analysis included 30,688 individuals (57.0 percent from Haiti).

The researchers noted 2,637 deaths during the study period, including 1,470 in Haiti and 1,167 from other sites. Over time, crude and weighted mortality rates decreased among all age groups. Life expectancy for people with HIV at age 20 years increased from 13.9 years in 2003 to 2008 to 61.2 years in 2013 to 2017 in Haiti and from 31.0 to 69.5 years in other sites. At the end of the study period, life expectancies were within 10 years of those of the general population (69.9 years in Haiti and 78.0 years in all other sites). Across time, disparities persisted in life expectancy among people with HIV by sex or HIV transmission risk factor, CD4 cell count, level of education, and history of tuberculosis at or before ART initiation.

"Our findings show that ART can narrow the gap in life expectancy for people with HIV in low-income and middle-income regions," the authors write.

Abstract/Full Text (subscription or payment may be required)

Editorial (subscription or payment may be required)

Copyright © 2020 HealthDay. All rights reserved. 

Supply Steady for Existing Patients Receiving Opioids During COVID-19

FRIDAY, April 30, 2021 (HealthDay News) -- Existing patients receiving opioid analgesics and buprenorphine for opioid use disorder have continued to receive medications during the COVID-19 pandemic, according to a study published online April 15 in JAMA Network Open.

Janet M. Currie, Ph.D., from Princeton University in New Jersey, and colleagues conducted a cross-sectional analysis to project use of opioid analgesics and buprenorphine for opioid use disorder from March 18 to Sept. 1, 2020, using a national database of retail prescriptions. For all, existing, and new patients, actual prescribing was compared to projected levels. A total of 452,691,261 prescriptions for opioid analgesics and buprenorphine were analyzed for 90,420,353 patients.

The researchers found that 1,877 million total morphine milligram equivalents of opioid analgesics were prescribed weekly from March 18 to May 19, 2020, compared with 1,843 projected (ratio, 102 percent). The weekly number of opioid-naive patients receiving opioids was 370,051 compared with 564,929 projected (66 percent of projected). Buprenorphine prescribing was as projected for existing patients, while fewer new patients received buprenorphine weekly (9,865 versus 12,008 projected; 82 percent). Opioid prescribing for new patients returned to 100 percent of projected from May 20 to Sept. 1, 2020, while the number of new patients receiving buprenorphine weekly was 90 percent (10,436 versus 11,613 projected).

"These results suggest that the pandemic reversed some of the improvement in access to buprenorphine for opioid use disorder that occurred during the past decade," the authors write.

Abstract/Full Text

Copyright © 2020 HealthDay. All rights reserved. 

Recomendación de vacunación.

Es recomendable vacunar a una persona de 54 años, diabético,  que tuvo covid hace 5 meses, estuvo con ventilación mecanica por 2 meses, actualmente en rehabilitación por miopatía, desnutrición, pérdida ponderal de 20kg. Daño pulmonar aún con utilización de oxígeno. Gracias.

vaccination anticovid et hepatite autoimmune

peut-on vacciner contre la Covid un patient qui a eu une hépatite autoimmune après vaccination antigrippale à 2 reprises (3 semaines après la vaccination)   dr ELKAÏM Robert

Vaccine induced Clots

Some cases of vaccine induced thrombosis, though rare have been reported after AZ and other Covid vaccinations. Will aspirin taken after Covid vaccination prevent such clots? Wondered what would the haemotologists advice in preventing vaccine induced clots; of course hoping 'not taking the vaccine' being not an option

What's the future of Medical Conferences?

COVID-19 changed the way physicians are engaging with each other. Following a full year of virtual conferences, physicians in the G-Med community came together to discuss their impressions, likes and dislikes in comparison to physical medical events.

G-Med's interactive platform has become the place where physicians come to expand their network, to update themselves on the latest medical news, share the latest news from each of their specialties and to fill the educational gap left by physical conferences.

Over 1,000 physicians voted within 48 hours in the latest G-Med poll about which type of conference they prefer. From EU countries, North and South American, Asia and the Middle East, physicians from 56 countries shared their preferences and visions on the future of medical conferences.


Here are some of your thoughts on Vaccination

Should patients under immunosuppressive treatment be vaccinated against Covid-19? How about those who have recovered from Covid, when should they get vaccinated?

Over the past months, the G-Med community has been discussing vaccination decisions, its effects and advisability to patients suffering from different pre conditions. Immunodepression, diabetes, rheumatological issues, among several others, were some of the conditions debated in the G-Med community in light of the decision to vaccinate against Covid-19. Our physician-only community continues to debate this crucial topic, and to share their insights with their colleagues. 

Thank you for your thoughtful contribution. Here are some of the issues discussed:

Here are some of your thoughts on Post-Covid

How are physicians from the G-Med community preparing themselves for the Post-Covid Era? What are Covid’s real impacts on the health of patients after recovering from the initial illness?

Over the past months, the G-Med community has been discussing one of tomorrow’s most challenging medical issues: Post-Covid conditions. From endocrinological conditions, neurological concerns, rheumatological impacts, among others, physicians from over 128 countries are sharing cases and receiving great insights from the community. 

Thank you for your thoughtful insights. Here are some of the issues discussed: